Vertex Pharmaceuticals, Inc. (VRTX)
542.62
-4.41
(-0.81%)
USD |
NASDAQ |
Nov 12, 16:00
543.14
+0.52
(+0.10%)
After-Hours: 05:23
Vertex Pharmaceuticals Free Cash Flow (Quarterly) : 545.80M for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 545.80M |
| June 30, 2026 | 1.013B |
| March 31, 2026 | 1.295B |
| December 31, 2025 | 348.60M |
| September 30, 2025 | 1.140B |
| June 30, 2025 | 927.40M |
| March 31, 2025 | 778.20M |
| December 31, 2024 | 492.00M |
| September 30, 2024 | 1.302B |
| June 30, 2024 | -3.830B |
| March 31, 2024 | 1.058B |
| December 31, 2023 | 118.50M |
| September 30, 2023 | 1.228B |
| June 30, 2023 | 1.075B |
| March 31, 2023 | 857.80M |
| December 31, 2022 | 1.045B |
| September 30, 2022 | 901.30M |
| June 30, 2022 | 1.086B |
| March 31, 2022 | 892.60M |
| December 31, 2021 | 933.28M |
| September 30, 2021 | 874.70M |
| June 30, 2021 | -249.60M |
| March 31, 2021 | 850.13M |
| December 31, 2020 | 443.84M |
| September 30, 2020 | 732.95M |
| Date | Value |
|---|---|
| June 30, 2020 | 1.021B |
| March 31, 2020 | 796.25M |
| December 31, 2019 | 429.25M |
| September 30, 2019 | 310.50M |
| June 30, 2019 | 447.39M |
| March 31, 2019 | 306.74M |
| December 31, 2018 | 298.86M |
| September 30, 2018 | 360.44M |
| June 30, 2018 | 292.09M |
| March 31, 2018 | 223.38M |
| December 31, 2017 | 184.91M |
| September 30, 2017 | -18.25M |
| June 30, 2017 | 164.34M |
| March 31, 2017 | 254.53M |
| December 31, 2016 | 130.02M |
| September 30, 2016 | 51.84M |
| June 30, 2016 | 24.78M |
| March 31, 2016 | -27.11M |
| December 31, 2015 | -27.56M |
| September 30, 2015 | -56.80M |
| June 30, 2015 | -108.63M |
| March 31, 2015 | -217.74M |
| December 31, 2014 | -136.79M |
| September 30, 2014 | -96.94M |
| June 30, 2014 | -139.62M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 271.15M |
| Gilead Sciences, Inc. | 4.798B |
| Regeneron Pharmaceuticals, Inc. | 1.427B |
| Sionna Therapeutics, Inc. | -18.72M |
| Amgen, Inc. | 3.654B |